Stephens Investment Management Group LLC Sells 180,141 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Stephens Investment Management Group LLC decreased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 9.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,752,068 shares of the specialty pharmaceutical company's stock after selling 180,141 shares during the quarter. Stephens Investment Management Group LLC owned about 3.17% of Supernus Pharmaceuticals worth $63,355,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Millennium Management LLC grew its position in Supernus Pharmaceuticals by 395.1% in the second quarter. Millennium Management LLC now owns 161,332 shares of the specialty pharmaceutical company's stock worth $4,316,000 after acquiring an additional 128,743 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Supernus Pharmaceuticals by 7.6% in the second quarter. The Manufacturers Life Insurance Company now owns 26,554 shares of the specialty pharmaceutical company's stock worth $710,000 after purchasing an additional 1,870 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Supernus Pharmaceuticals by 97.1% in the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company's stock worth $25,000 after purchasing an additional 398 shares in the last quarter. Exchange Traded Concepts LLC acquired a new position in Supernus Pharmaceuticals during the third quarter worth $672,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Supernus Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company's stock valued at $61,000 after buying an additional 352 shares in the last quarter.

Supernus Pharmaceuticals Trading Up 1.9 %

SUPN stock traded up $0.72 during midday trading on Tuesday, hitting $38.65. The stock had a trading volume of 312,050 shares, compared to its average volume of 359,183. The firm has a market capitalization of $2.13 billion, a price-to-earnings ratio of 36.12 and a beta of 0.90. The stock has a 50-day simple moving average of $37.38 and a 200 day simple moving average of $34.90. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $40.28.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on SUPN. Cowen reiterated a "buy" rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Cantor Fitzgerald started coverage on Supernus Pharmaceuticals in a research report on Monday, January 6th. They set an "overweight" rating and a $57.00 target price for the company. Finally, Piper Sandler reissued a "neutral" rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Insider Buying and Selling at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the sale, the vice president now owns 10,149 shares in the company, valued at $402,915.30. This trade represents a 48.29 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 9.30% of the company's stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.